Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lead Therapeutics Draws Investors

November 19, 2007 | A version of this story appeared in Volume 85, Issue 47

San Francisco Bay Area-based Lead Therapeutics, a small-molecule drug discovery firm that plans to conduct most of its research in China, has raised $17 million from a group of private equity investors including Pappas Ventures, ProQuest Investments, and Mustang Ventures. Also putting money into Lead is China Gateway Life Science, the investment arm of the Chinese contract research firm ShangPharma. As part of the deal, Lead will start a research collaboration with ShangPharma's Shanghai ChemPartner subsidiary.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.